Organization (Industry)
Qilu Pharmaceutical Co., Ltd. (China)
ClinicalTrials.gov lists Qilu Pharmaceutical Co., Ltd. (China) as lead sponsor of 203 trials. It has 266 active development programs and 58 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 54 registered with a 2026 start date. The hollow diamonds on the dashed line are a forecast of the full-year count, planned starts included: about 61 in 2026 and about 56 in 2027, the average of the 24 months through September, counted as registered and carried forward. The columns, the lighter one included, count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. This method has not been backtested on organizations. In backtests on conditions with as many trial starts a year as this organization (20 to 100), forecasts made part-way through the year were typically off by about 18 percent and ran about 14 percent low against the count later registered; forecasts made before the year began were off by about 26 percent and ran about 20 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.
This page covers Qilu Pharmaceutical Co., Ltd. (China): 203 lead-sponsored trials and 1 legal-entity registration.
Disease areas (94)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Lung Neoplasms | 22 |
| Carcinoma, Non-Small-Cell Lung | 14 |
| Colorectal Neoplasms | 9 |
| Breast Neoplasms | 8 |
| Multiple Myeloma | 7 |
Showing 5 of 94 disease areas.
Trials by start year as sponsor or collaborator (11)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 54 |
| 2025 | 60 |
| 2024 | 20 |
| 2023 | 26 |
| 2022 | 17 |
| 2021 | 17 |
| 2020 | 14 |
| 2019 | 13 |
| 2018 | 8 |
| 2017 | 6 |
Showing 10 of 11 years.
Prediction, not a registry value: median of 35 months from start to primary completion across 46 trials still running at the 2026-10-09 snapshot; registered median of 8 months across 37 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (266)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| POMALIDOMIDE | Multiple Myeloma | Phase 3 | 4 |
| DEXAMETHASONE | Multiple Myeloma | Phase 3 | 4 |
| QLC7401 | Dyslipidemias | Phase 3 | 3 |
| QLC7401 | Hyperlipidemias | Phase 3 | 3 |
| QLC7401 | Hyperlipoproteinemia Type II | Phase 3 | 3 |
Showing 5 of 266 active programs.
Approved assets (58)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| PEGFILGRASTIM | 2 |
| Tafamidis Meglumine Soft Capsules | 1 |
| Dimethyl Fumarate Enteric-coated Capsules | 1 |
| BEVACIZUMAB | 7 |
| "Capecitabine" | 7 |
Showing 5 of 58 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 78% hit target (n=18) | 56% on time (n=18) |
Journals published in (23)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Journal of hematology & oncology | 2 |
| Signal transduction and targeted therapy | 2 |
| Advances in therapy | 1 |
| Annals of hematology | 1 |
| Annals of translational medicine | 1 |
Showing 5 of 23 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 11 | 3 | 2025-09-16 |
FDA inspection record (1)
| Latest classification | Inspections |
|---|---|
| VAI | 19 |
FDA import refusals (1)
| Refused import lines | Latest refusal |
|---|---|
| 5 | 2023-10-03 |
Manufacturing and distribution sites (10)
Shown in this order: severity rank then name.
| Facility | Location | Regulators | Member organization |
|---|---|---|---|
| Qilu Pharmaceutical Co., Ltd. (Biological Industrial Park) | Jinan, CN | FDA | |
| Qilu Pharmaceutical Co., Ltd.(High Tech Zone Site) | Jinan, CN | EMA, FDA, Health Canada | |
| Qilu Pharmaceutical (Hainan) Co., Ltd. | Haikou, CN | EMA, FDA, Health Canada | |
| Qilu Pharmaceutical Co., Ltd. | Jinan, CN | EMA, FDA, Health Canada | |
| Qilu Pharmaceutical Co., Ltd. (Biological Product Plant) | Jinan, CN | EMA, FDA, Health Canada |
Showing 5 of 10 sites.
Organization relationships (41)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Shanxi Provincial Cancer Hospital | Co sponsors trial with | 1 |
| Pharmascience Inc. (Canada) | Co sponsors trial with | 1 |
| Viatris | Co sponsors trial with | 1 |
| Apotex (Canada) | Co sponsors trial with | 1 |
| GSK plc | Co sponsors trial with | 1 |
Showing 5 of 41 relationships.
Latest dated events (272)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-11-24 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-11-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-11 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-10-15 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-10 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 272 events.
Biomarker capability evidence (604)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ACE | Trial sponsor | Named in trial inclusion criteria |
| AGT | Trial sponsor | Named in trial inclusion criteria |
| ALB | Trial sponsor | Named in trial inclusion criteria |
| ALB | Trial collaborator | Named in trial inclusion criteria |
| ALB | Trial collaborator | Named in trial inclusion criteria |
Showing 5 of 604 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda recalls, climate targets, as filed, workforce and board diversity, as filed, clia clinical laboratory certificates, and biomarkers this organization publishes on.